Trading in Novo Nordisk shares by board members, executives and
associated persons as reported to Novo Nordisk on 1 November 2007
In accordance with Section 28a of the Danish Securities Trading Act,
Novo Nordisk is required on a daily basis to publish trading in Novo
Nordisk shares by the company's board members, executives and their
associated persons as reported by those persons to Novo Nordisk.
Please find below a statement of such trading in shares issued by
Novo Nordisk.
+-------------------------------------------------------------------+
| Name | Kurt Anker Nielsen |
|----------------------------------+--------------------------------|
| Reason for reporting | Member of the Board of |
| | Directors |
|----------------------------------+--------------------------------|
| Financial instrument and ID code | Novo Nordisk B shares DK |
| | 001028081 |
|----------------------------------+--------------------------------|
| Type of transaction | Sale of shares |
|----------------------------------+--------------------------------|
| Date of transaction | 1 November 2007 |
|----------------------------------+--------------------------------|
| Place of transaction | OMX The Nordic Exchange |
|----------------------------------+--------------------------------|
| Volume of transaction | 5,000 shares |
|----------------------------------+--------------------------------|
| Total value of transaction | DKK 3,205,000 |
+-------------------------------------------------------------------+
+-------------------------------------------------------------------+
| Name | Søren Thuesen Pedersen |
|---------------------------------+---------------------------------|
| Reason for reporting | Member of the Board of |
| | Directors |
|---------------------------------+---------------------------------|
| Financial instrument and ID | Novo Nordisk B shares DK |
| code | 001028081 |
|---------------------------------+---------------------------------|
| Type of transaction | Purchase of shares |
|---------------------------------+---------------------------------|
| Date of transaction | 31 October 2007 |
|---------------------------------+---------------------------------|
| Place of transaction | Copenhagen Stock Exchange |
|---------------------------------+---------------------------------|
| Volume of transaction | 25 shares |
|---------------------------------+---------------------------------|
| Total value of transaction | DKK 15,275 |
+-------------------------------------------------------------------+
+-------------------------------------------------------------------+
| Name | Søren Thuesen Pedersen |
|---------------------------------+---------------------------------|
| Reason for reporting | Member of the Board of |
| | Directors |
|---------------------------------+---------------------------------|
| Financial instrument and ID | Novo Nordisk B shares DK |
| code | 001028081 |
|---------------------------------+---------------------------------|
| Type of transaction | Sale of shares |
|---------------------------------+---------------------------------|
| Date of transaction | 1 November 2007 |
|---------------------------------+---------------------------------|
| Place of transaction | Copenhagen Stock Exchange |
|---------------------------------+---------------------------------|
| Volume of transaction | 25 shares |
|---------------------------------+---------------------------------|
| Total value of transaction | DKK 15,850 |
+-------------------------------------------------------------------+
+-------------------------------------------------------------------+
| Name | Lars Rebien Sørensen |
|-----------------------------+-------------------------------------|
| Reason for reporting | Chief Executive Officer |
|-----------------------------+-------------------------------------|
| Financial instrument and ID | Novo Nordisk B shares DK 001028081 |
| code | |
|-----------------------------+-------------------------------------|
| Type of transaction | Exercise of options (purchase of |
| | shares) |
|-----------------------------+-------------------------------------|
| Date of transaction | 1 November 2007 |
|-----------------------------+-------------------------------------|
| Place of transaction | Copenhagen Stock Exchange |
|-----------------------------+-------------------------------------|
| Volume of transaction | 10,000 shares |
|-----------------------------+-------------------------------------|
| Total value of transaction | DKK 1,980,000 |
+-------------------------------------------------------------------+
+-------------------------------------------------------------------+
| Name | Lars Rebien Sørensen |
|---------------------------------+---------------------------------|
| Reason for reporting | Chief Executive Officer |
|---------------------------------+---------------------------------|
| Financial instrument and ID | Novo Nordisk B shares DK |
| code | 001028081 |
|---------------------------------+---------------------------------|
| Type of transaction | Sale of shares |
|---------------------------------+---------------------------------|
| Date of transaction | 1 November 2007 |
|---------------------------------+---------------------------------|
| Place of transaction | Copenhagen Stock Exchange |
|---------------------------------+---------------------------------|
| Volume of transaction | 10,000 shares |
|---------------------------------+---------------------------------|
| Total value of transaction | DKK 6,330,550 |
+-------------------------------------------------------------------+
Definitions and background information:
Publication
Publication shall take place the day after Novo Nordisk receives
sufficient information on the trading. Publication is only required
when the total amount of transactions of a specific board
member/executive and his/her associated persons in any one calendar
year has reached 5,000 euros.
Who are board members, executives and associated persons?
Board members and executives are members of the Board of Directors
and Executive Management, respectively, of Novo Nordisk A/S.
Associated persons are defined as the following persons associated to
a board member/executive: 1) spouse or cohabitant, 2) children under
the age of 18 years, 3) relatives defined as brothers, sisters,
parents, grandparents etc, children, grandchildren etc who have
shared the same household with a board member/executive for at least
one year, and 4) any legal person, including a company, a foundation
or a partnership, which is controlled directly or indirectly by a
board member/executive and/or a person mentioned in 1)-3), or to
which a board member/executive and/or a person mentioned in 1)-3) has
managerial responsibilities or economic interests substantially
equivalent to the legal person.
What is trading/transaction?
Trading is any kind of transaction, including shares purchased or
otherwise acquired, shares sold or otherwise disposed, gifts,
mortgages and grants and exercise of options, but not heritage.
What is financial instrument and ID code?
Financial instrument includes shares listed on the Copenhagen Stock
Exchange and London Stock Exchange as well as ADRs listed on New York
Stock Exchange, except for ADRs held in 401(k) retirement plan by
US-based employees. The ID code is the code (ISIN DK001028081) of the
Novo Nordisk share on the Copenhagen Stock Exchange, the code (NVOB)
on London Stock Exchange or the code (NVO) on New York Stock
Exchange.
What is date and place of transaction?
Date of transaction is the actual transaction date. The place of
transaction is the actual place of transaction, ie Copenhagen Stock
Exchange, London Stock Exchange or New York Stock Exchange.
What is volume and value of transaction?
The volume of transaction is the number of shares (of DKK 2 nominal
value) or other financial instruments traded. The transaction value
is the number of shares traded multiplied by the transaction price.
The exchange rate of the Danish Central Bank (Nationalbanken) on the
date of transaction is used for calculating the transaction value in
DKK in case of shares traded on London Stock Exchange and ADRs listed
on New York Stock Exchange.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. The company has the broadest diabetes product portfolio in the
industry, including the most advanced products within the area of
insulin delivery systems. In addition, Novo Nordisk has a leading
position within areas such as haemostasis management, growth hormone
therapy and hormone replacement therapy. Novo Nordisk manufactures
and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and
society. With headquarters in Denmark, Novo Nordisk employs
approximately 25,800 employees in 79 countries, and markets its
products in 179 countries. Novo Nordisk's B shares are listed on the
stock exchanges in Copenhagen and London. Its ADRs are listed on the
New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.
For further information plase contact
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com cqfr@novonordisk.com
Stock Exchange Announcement no 30 / 2007